Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.
Journal: Human vaccines & immunotherapeutics
Published: August 21, 2015
Finishing what was started: an analysis of theater research conducted from 2010 to 2012.
Journal: Military medicine
Published: March 10, 2015
Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.
Journal: PloS one
Published: April 08, 2014
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Journal: Human vaccines & immunotherapeutics
Published: August 01, 2013
First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.
Journal: Vaccine
Published: May 08, 2013
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).
Journal: Malaria journal
Published: March 02, 2013
A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus.
Journal: Vaccine
Published: January 15, 2013
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
Journal: PloS one
Published: September 21, 2012
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
Journal: PloS one
Published: November 12, 2010
Showing 1-11 of 11
Last Updated: 09/26/2026